Genentech (DNA) Said Avastin Plus Interferon Therapy Improved Progression-Free Survival in RCC
More News related to DNA
- Piper Jaffray Reiterates an 'Overweight' on Regeneron Pharmaceuticals (REGN); Raises Price Target
- Biogen Idec (BIIB) Announces Decision By Arbitration Panel in Issues with Genentech (DNA)
- Genentech (DNA) Announces Voluntary Withdrawal of Raptiva from the U.S. Market
- FDA ODA Committee Recommends Accelerated Approval of Genentech's (DNA) Avastin for Brain Cancer
- Genentech (DNA) said FDA committee unamiously recommends accelerated approval of Avastin in brain cancer
More News related to FDA
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
Genentech, Inc. (NYSE: DNA) said interim analysis shows that a randomized Phase III clinical study of Avastin in combination with interferon alfa-2a therapy in patients with first-line metastatic renal cell carcinoma met the primary analysis endpoint by significantly improving progression-free survival compared to interferon alfa-2a therapy alone.
In addition, the early analysis indicates a trend toward improvement in overall survival in the Avastin plus interferon arm.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
